drugset / Trial / NCT05247203
Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-center, open-label, phase I study.
Timeline
- Start
- 2022-05-11
- Primary completion
- 2023-10-25
- Completion
- 2023-11-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telitacicept | Protein / enzyme biologic | 80 mg | Subcutaneous |
| Subject | Telitacicept | Protein / enzyme biologic | 160 mg | Subcutaneous |
| Subject | Telitacicept | Protein / enzyme biologic | 240 mg | Subcutaneous |
| Background | Azathioprine | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Cyclosporine | Peptide | — | — |
| Background | Leflunomide | Small molecule | — | — |
| Background | Methotrexate | Small molecule | — | — |
| Background | Mycophenolate Mofetil | Small molecule | — | — |
| Background | Tacrolimus | Small molecule | — | — |